Gynecologic care in hematopoietic stem cell transplant patients: A review

Obstetrical and Gynecological Survey

Volumn 65, Issue 10, 2010, Pages 668-679

  Milroy, Colleen L ^a   Jones, Kirtly Parker ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CALCIUM; CLOBETASOL; CONJUGATED ESTROGEN; CYCLOSPORIN; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GLUCOCORTICOID; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HYDROCORTISONE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PAMIDRONIC ACID; PERMANGANATE POTASSIUM; PREDNISONE; PROGESTERONE; RISEDRONIC ACID; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID;

ANDROGEN DEFICIENCY; CANCER SCREENING; CONTRACEPTION; COUNSELING; FERTILITY PRESERVATION; GENITAL TRACT INFECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GYNECOLOGIC CARE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LIVER TOXICITY; MEDICAL RESEARCH; MENORRHAGIA; MENSTRUATION; MENSTRUATION DISORDER; OSTEOPENIA; OSTEOPOROSIS; PATIENT EDUCATION; PHYSICAL EXAMINATION; PREGNANCY; PREMATURE OVARIAN FAILURE; PRESERVATION; PREVENTIVE MEDICINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCREENING; SEXUAL HEALTH; SEXUALITY; UNITED STATES; VAGINA BLEEDING; VAGINAL DRYNESS; VEIN THROMBOSIS;

CONTRACEPTION; EARLY DETECTION OF CANCER; FEMALE; GENITAL DISEASES, FEMALE; GYNECOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HORMONE REPLACEMENT THERAPY; HUMANS; PATIENT CARE; PREGNANCY; SEXUALITY;

EID: 78651295993     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e31820955be     Document Type: Review

References (89)

1. Program NDM. NDMP by cell source. 2009. Available at: http://www.marrow.org/PHYSICIAN/images/nmdp-transplants-b1. jpg. Cited January 16, 2010.
2. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allo-geneic hematopoietic cell transplantation. Blood 2009;113: 1175-1183.
3. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after he-matopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant 2006;37:249-261.
4. Hasegawa W, Pond GR, Rifkind JT, et al. Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant 2005;35: 51-55.
5. Savani BN, Stratton P, Shenoy A, et al. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation- implications for screening and HPV vaccination. Biol Blood Marrow Transplant 2008;14:1072-1075.
6. Sasadeusz J, Kelly H, Szer J, et al. Abnormal cervical cytology in bone marrow transplant recipients. Bone Marrow Transplant 2001;28:393-397.
7. Daneshpouy M, Socie G, Clavel C, et al. Human papillomavi-rus infection and anogenital condyloma in bone marrow transplant recipients. Transplantation 2001;71:167-169.
8. Ganguly N, Waller S, Stasik CJ, et al. Giant anal condyloma-tosis after allogeneic bone marrow transplantation: a rare complication of human papilloma virus infection. Transpl Infect Dis 2008;10:56-58.
9. Frydman R, Parneix I, Belaisch-Allart J, et al. LHRH agonists in IVF: different methods of utilization and comparison with previous ovulation stimulation treatments. Hum Reprod 1988;3: 559-561.
10. Garnick MB, Campion M. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol 2000;4:275-277.
11. Tomera K, Gleason D, Gittelman M, et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001;165:1585-1589.
12. Broqua P, Riviere PJ, Conn PM, et al. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 2002;301: 95-102.
13. Sica S, Salutari P, Di Mario A, et al. Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis. Am J Hematol 1996; 51:248-249.
14. Chiusolo P, Salutari P, Sica S, et al. Luteinizing hormone-releasing hormone analogue: leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation. Bone Marrow Transplant 1998;21:821-823.
15. Kaunitz AM. Injectable contraception. New and existing options. Obstet Gynecol Clin North Am 2000;27:741-780.
16. Kaunitz AM. Injectable long-acting contraceptives. Clin Ob-stet Gynecol 2001;44:73-91.
17. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception 2003;68:75-87.
18. Cowan BD, Morrison JC. Management of abnormal genital bleeding in girls and women. N Engl J Med 1991;324:1710-1715.
19. Rosenfeld JA. Treatment decisions in the management of menorrhagia. Medscape Womens Health 1997;2:6.
20. Laros RK Jr. Therapeutic amenorrhea in hematologic disorders. Obstet Gynecol 1971;38:589-593.
21. Kaunitz AM. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. Int J Fertil Wom-ens Med 1998;43:73-83.
22. Elder MG. Injectable contraception. Clin Obstet Gynaecol 1984;11:723-741.
23. Food and Drug Administration. 2004. Available at: www.fda. gov/Safety/MedWatch/SafetyInformation/SafetyAlertsfor HumanMedicalProducts/ ucm154784.htm. Cited January 20, 2010.
24. Meirow D, Rabinovici J, Katz D, et al. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer 2006;107:1634-1641.
25. Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonado-toxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 2005;2005:40-43.
26. Grady MC. Preconception and the young cancer survivor. Matern Child Health J 2006;10(suppl 5):S165-S168.
27. Mertens AC, Ramsay NK, Kouris S, et al. Patterns of gonadal dysfunction following bone marrow transplantation. Bone Marrow Transplant 1998;22:345-350.
28. Schimmer AD, Quatermain M, Imrie K, et al. Ovarian function after autologous bone marrow transplantation. J Clin Oncol 1998;16:2359-2363.
29. Liu J, Malhotra R, Voltarelli J, et al. Ovarian recovery after stem cell transplantation. Bone Marrow Transplant 2008;41: 275-278.
30. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001; 7:535-543.
31. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931.
32. Oktay K, Sonmezer M, Oktem O, et al. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 2007;12:1055-1066.
33. Gupta P, Sturdee DW, Palin SL, et al. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 2006;9:49-58.
34. Bordeleau L, Pritchard K, Goodwin P, et al. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin Ther 2007;29:230-241.
35. Piccioni P, Scirpa P, D'Emilio I, et al. Hormonal replacement therapy after stem cell transplantation. Maturitas 2004;49: 327-333.
36. Clarke K, Basser RL. The role of platelet growth factors in cancer therapy. Stem Cells 1996;14(suppl 1):274-280.
37. Bacigalupo A. Haemopoietic stem cell transplants: the impact of haemorrhagic complications. Blood Rev 2003;17(suppl 1): S6-S10.
38. Hagglund H, Remberger M, Klaesson S, et al. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998;92:4568-4572.
39. Sica S, Salutari P, Chiusolo P, et al. Hormonal therapy after stem cell transplantation and risk of veno-occlusive disease. Blood 1999;93:3154.
40. Sica S, Sora F, Laurenti L, et al. The treatment of menorrhagia in female stem cell transplant recipients. Bone Marrow Transplant 2005;35:827.
41. Amsterdam A, Jakubowski A, Castro-Malaspina H, et al. Treatment of menorrhagia in women undergoing hematopoi-etic stem cell transplantation. Bone Marrow Transplant 2004; 34:363-366.
42. Rosenfeld JA. Treatment of menorrhagia due to dysfunctional uterine bleeding. Am Fam Physician 1996;53:165-172.
43. Munro MG. Dysfunctional uterine bleeding: advances in diagnosis and treatment. Curr Opin Obstet Gynecol 2001;13:475-489.
44. Reich H, Ribeiro SC, Vidali A. Hysterectomy as treatment for dysfunctional uterine bleeding. Baillieres Best Pract Res Clin Obstet Gynaecol 1999;13:251-269.
45. Rebar RW. Premature ovarian failure. Obstet Gynecol 2009; 113:1355-1363.
46. Tierney KD, Facione N, Padilla G, et al. Altered sexual health and quality of life in women prior to hematopoietic cell transplantation. Eur J Oncol Nurs 2007;11:298-308.
47. van der Stege JG, Groen H, van Zadelhoff SJ, et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 2008;15:23-31.
48. Hartmann BW, Kirchengast S, Albrecht A, et al. Androgen serum levels in women with premature ovarian failure compared to fertile and menopausal controls. Gynecol Obstet Invest 1997;44:127-131.
49. Elias AN, Pandian MR, Rojas FJ. Serum levels of andro-stenedione, testosterone and dehydroepiandrosterone sulfate in patients with premature ovarian failure to age-matched menstruating controls. Gynecol Obstet Invest 1997;43:47-48.
50. Barton DL, Wender DB, Sloan JA, et al. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. J Natl Cancer Inst 2007; 99:672-679.
51. Humphreys CT, Tallman B, Altmaier EM, et al. Sexual functioning in patients undergoing bone marrow transplantation: a longitudinal study. Bone Marrow Transplant 2007;39:491-496.
52. Cust MP, Whitehead MI, Powles R, et al. Consequences and treatment of ovarian failure after total body irradiation for leukaemia. BMJ 1989;299:1494-1497. (Pubitemid 20019133)
53. Claessens JJ, Beerendonk CC, Schattenberg AV. Quality of life, reproduction and sexuality after stem cell transplantation with partially T-cell-depleted grafts and after conditioning with a regimen including total body irradiation. Bone Marrow Transplant 2006;37:831-836.
54. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83-92.
55. Schover LR, Evans RB, von Eschenbach AC. Sexual rehabilitation in a cancer center: diagnosis and outcome in 384 consultations. Arch Sex Behav 1987;16:445-461.
56. Schover LR, Jenkins R, Sui D, et al. Randomized trial of peer counseling on reproductive health in African American breast cancer survivors. J Clin Oncol 2006;24:1620-1626.
57. Spinelli S, Chiodi S, Costantini S, et al. Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation. Haematologica 2003;88:1163-1168.
58. Stratton P, Turner ML, Childs R, et al. Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation. Obstet Gynecol 2007;110:1041-1049. (Pubitemid 350059409)
59. Norian JM, Stratton P. Labial fusion: a rare complication of chronic graft-versus-host disease. Obstet Gynecol 2008; 112(2 pt 2):437-439.
60. Corson SL, Sullivan K, Batzer F, et al. Gynecologic manifestations of chronic graft-versus-host disease. Obstet Gynecol 1982;60:488-492.
61. Zantomio D, Grigg AP, MacGregor L, et al. Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management. Bone Marrow Transplant 2006;38:567-572.
62. Spiryda LB, Laufer MR, Soiffer RJ, et al. Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transplant 2003;9:760-765.
63. Costantini S, Chiodi S, Spinelli S, et al. Complete vaginal obstruction caused by chronic graft-versus-host disease after haematopoietic stem cell transplantation: diagnosis and treatment. J Obstet Gynaecol 2004;24:591-595.
64. Martinelli G, Alessandrino EP, Bernasconi P, et al. Fournier's gangrene: a clinical presentation of necrotizing fasciitis after bone marrow transplantation. Bone Marrow Transplant 1998; 22:1023-1026.
65. Stern JM, Sullivan KM, Ott SM, et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant 2001;7:257-264.
66. Ebeling PR. Defective osteoblast function may be responsible for bone loss from the proximal femur despite pamidronate therapy. J Clin Endocrinol Metab 2005;90:4414-4416.
67. Tauchmanova L, Selleri C, Rosa GD, et al. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer 2002;95:1076-1084.
68. Tauchmanova L, De Rosa G, Serio B, et al. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review. Cancer 2003;97:2453-2461.
69. Schulte CM, Beelen DW. Avascular osteonecrosis after allo-geneic hematopoietic stem-cell transplantation: diagnosis and gender matter. Transplantation 2004;78:1055-1063.
70. Castaneda S, Carmona L, Carvajal I, et al. Reduction of bone mass in women after bone marrow transplantation. Calcif Tissue Int 1997;60:343-347.
71. Katz IA, Epstein S. Posttransplantation bone disease. J Bone Miner Res 1992;7:123-126.
72. Kananen K, Volin L, Tahtela R, et al. Recovery of bone mass and normalization of bone turnover in long-term survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant 2002;29:33-39.
73. Ebeling PR, Akesson K. Role of biochemical markers in the management of osteoporosis. Best Pract Res Clin Rheumatol 2001;15:385-400.
74. Valimaki MJ, Kinnunen K, Volin L, et al. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 1999;23:355-361. (Pubitemid 29105959)
75. Tauchmanova L, De Simone G, Musella T, et al. Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation. Bone Marrow Transplant 2006;37:81-88.
76. Ebeling PR, Thomas DM, Erbas B, et al. Mechanisms of bone loss following allogeneic and autologous hematopoietic stem cell transplantation. J Bone Miner Res 1999;14:342-350.
77. Kananen K, Volin L, Laitinen K, et al. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidr-onate. J Clin Endocrinol Metab 2005;90:3877-3885.
78. Grigg AP, Shuttleworth P, Reynolds J, et al. Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2006;91:3835-3843.
79. Ebeling PR. Approach to the patient with transplantation-related bone loss. J Clin Endocrinol Metab 2009;94:1483-1490.
80. Lowe T, Bhatia S, Somlo G. Second malignancies after allo-geneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007;13:1121-1134.
81. Friedman DL, Rovo A, Leisenring W, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood 2008;111:939-944.
82. Group CsO. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers. Available at: http://www. survivorshipguidelines.org/pdf/LTFUGuidelines.pdf. Cited 2010.
83. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 99: management of abnormal cervical cytology and histology. Obstet Gynecol 2008;112:1419-1444.
84. Heard I. Prevention of cervical cancer in women with HIV. Curr Opin HIV AIDS 2009;4:68-73.
85. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006;24(suppl 3):S140-S146.
86. Salooja N, Szydlo RM, Socie G, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 2001;358:271-276.
87. Carter A, Robison LL, Francisco L, et al. Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone Marrow Transplant 2006;37:1023-1029.
88. Sanders JE, Buckner CD, Amos D, et al. Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol 1988;6:813-818.
89. Au WY, Leung WC. Challenges and pitfalls in prenatal screening in pregnancies involving allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2007;39:379-382.